Welcome to BioSeeker Group!

Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 6050
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
Acceleron Pharma
Access
ACT Biotech
Active Biotech
Advanced Life Sciences
Advantagene
Advenchen
AEgera
AEterna Zentaris
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AndroBioSys
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
Apogee Biotechnology
Apogenix
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
BioInvent
BioLineRx
BioMarin
Biomas
BioNetWorks
Bionovo
BioSante
Biostar
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Cel-Sci
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celsion
Center of Molecular Immunology
Cephalon
CerRx
ChemoCentryx
Chemokine Therapeutics
Chlorogen
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Colby
CombinatoRx
CompleGen
Compugen
CoNCERT Pharmaceuticals
Coronado Biosciences
Cosmo Bioscience
Critical Outcome Technologies
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dongkook Pharm
Dyax
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Galapagos
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
GPC Biotech
Green Cross
GTx
Hanmi
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intellikine
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karo Bio
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
Molecular Insight
Molecular LogiX
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Pathway Therapeutics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Rosetta Genomics
Salzburg Therapeutics
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Senesco Technologies
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Sigma-Tau
Silence Therapeutics
Soligenix
Sophiris Bio
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synta Pharmaceuticals
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
Taxolog
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Twinstrand Therapeutics
UCB
UMN Pharma
Unigene
United Biomedical
ValiRx
VasGene Therapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroMed
ViroTarg
VM Discovery
Wyeth
Xcovery
Xencor
Xerion
Xoma
YM BioSciences
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
AC-480
adecatumumab
aderbasib
AE-37
AEG-35156
AEZS-108
AF-802
afatinib
aflibercept
ALT-801
alvocidib
AME-133
AMG-386
amonafide dihydrochloride
amonafide malate
Angiozyme
apatinib
APC-100
APG-101
APR-246
AR-42
ARC-100
ARQ-197
AS-101
AS-1411
AT-7519
AT-9283
atrasentan
AVX-701
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
bicalutamide
BMS-690514
BMS-754807
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
buserelin
BZL-101
Cabozantinib
CAL-101
canfosfamide hydrochloride
carlumab
CBP-501
CC-223
cediranib
celecoxib
cenersen
cetuximab
cintredekin besudotox
cixutumumab
conatumumab
crizotinib
crolibulin
custirsen
dacomitinib
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dulanermin
dutasteride
E-75
endoxifen
ENMD-2076
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
foretinib
fosbretabulin tromethamine
fostamatinib disodium
fulvestrant
gataparsen
GDC-0980
gefitinib
goserelin
GSK-2118436
GT-111
GTx-758
GVAX
GVX-3322
GX-301
HE-3235
histrelin
ibritumomab tiuxetan
IC-83
icrucumab
idronoxil
imatinib mesilate
imetelstat
INCB-028060
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
irosustat
ispinesib mesylate
JI-101
kahalalide F
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
linsitinib
LIP-131I
LipoVIL12
litronesib
lonaprisan
LOR-2040
LOR-2501
lumiliximab
LY-2090314
LY-2275796
mapatumumab
masitinib
MCS-110
MDV-3100
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
mocetinostat
motesanib diphosphate
motexafin gadolinium
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
navitoclax
neratinib
nilotinib
nilutamide
nimotuzumab
noscapine
NPB-001-056
obinutuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
onartuzumab
Oncohist
orteronel
OSI-027
OTS-102
ozarelix
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PD-0332991
pegdinetanib
perifosine
pertuzumab
PHA-848125AC
plitidepsin
PLX-3397
ponatinib
ProstAtak
PROSTVAC
PRX-302
PX-12
PX-866
quarfloxacin
quinacrine
quizartinib dihydrochloride
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
RX-0201-N
sagopilone
sargramostim
SB-939
SCH-900776
seliciclib
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
TAK-448
talmapimod
tandutinib
tasquinimod
telatinib
temsirolimus
Tenarad
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
tivozanib
TL-32711
TOK-001
toremifene citrate
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Melanoma. Learn More